About NovoSeven® RT

What is NovoSeven® RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable?

NovoSeven® RT is the only recombinant Factor VII product available for the treatment of bleeding episodes and prevention of surgical bleeding in patients with hemophilia A or B with inhibitors to FVIII or FIX, patients with acquired hemophilia, and patients with FVII deficiency.

How Does NovoSeven® RT Work?

NovoSeven® RT works the same way as NovoSeven®, which is why it's as effective and safe for stopping bleeds quickly and safely.

There are 13 factors in the clotting process. Clotting happens when each factor works together in the right order. The clotting process can be slowed or stopped if one factor is blocked or missing. In order for a stable clot to form, the deficient factor in the blood-clotting process must be replaced or bypassed. Learn more about the clotting process

NovoSeven® RT is called a bypassing agent because it skips the need for Factor VIII or IX in people with inhibitors, instead activating Factor X directly. For people with FVII deficiency, NovoSeven® RT is used to replace the missing factor, so the clotting process can continue.

NovoSeven® RT in Action

  • mechanism of action 01

    NovoSeven® RT is activated Factor VII. NovoSeven® RT enters the bloodstream and travels to the site of the injury.

  • mechanism of action 02

    NovoSeven® RT bypasses the need for Factor VIII or IX. It allows the clotting factors to work together. It helps activate Factor X to make clotting material.

  • mechanism of action 03

    NovoSeven® RT begins working in minutes. Clotting begins at the site of the injury.

  • mechanism of action 04

    A stable fibrin clot is formed. The bleed is usually stopped after 5 hours.

See NovoSeven® RT in action—View an animated demonstration of how NovoSeven® RT works.